NAD+ and Cardiovascular Health After 40: The Heart Side of Cellular Aging

There is a moment, somewhere in your forties, when the body starts keeping a different kind of score. The blood pressure reading at your annual physical creeps up a few points. A flight of stairs that used to be nothing asks for a breath at the top. Your doctor mentions the word "arterial stiffness," and suddenly the abstract idea of aging has a number attached to it. For most people, none of this is dramatic. It is just the quiet arithmetic of getting older.

What rarely gets discussed in that exam room is the cellular chemistry underneath those numbers. The conversation about NAD+ and cardiovascular health after 40 is one of the more interesting frontiers in longevity research right now, because it connects a molecule most people have never heard of to the system that arguably matters most for how long and how well we live. Your cardiovascular system does not age in isolation. It ages alongside the energy machinery inside every cell that keeps your arteries flexible and your heart muscle fueled.

What NAD+ Actually Does Inside Your Cardiovascular System

NAD+, short for nicotinamide adenine dinucleotide, is a coenzyme present in every living cell. If that sounds dry, consider what it does. NAD+ is essential for turning the food you eat into usable energy, for repairing damaged DNA, and for activating a family of proteins called sirtuins that help regulate how cells respond to stress and aging.

The cardiovascular system is unusually dependent on this machinery. Your heart never rests. It is one of the most metabolically demanding organs in the body, and it relies on a constant supply of cellular energy to keep contracting. The endothelium, the thin single layer of cells lining your blood vessels, is just as demanding. These cells manage blood flow, regulate inflammation, and produce nitric oxide, the signaling molecule that tells your arteries when to relax and widen.

Here is the problem researchers keep running into: NAD+ levels decline with age. As that decline sets in, the energy and repair systems that keep the heart and blood vessels resilient have less to work with. The question that has driven a decade of studies is whether restoring NAD+ can help offset some of that decline.

The Aging Decline Nobody Warns You About

The downward drift of NAD+ is not a fringe theory. It has been documented across multiple human tissues including blood, muscle, and skin, and it tracks closely with the years. The reasons are layered. The body's NAD+ production slows, while at the same time enzymes that consume NAD+, many of them activated by the chronic low-grade inflammation and DNA damage that accumulate with age, draw down the available pool faster.

For the cardiovascular system, this matters in a specific way. When NAD+ falls, sirtuin activity falls with it, and sirtuins are deeply involved in keeping arteries healthy. They help control oxidative stress, support the production of nitric oxide, and influence the structural proteins that determine whether an artery stays supple or turns stiff. A stiffer artery means higher systolic blood pressure and more work for the heart, which is exactly the pattern that tends to emerge in midlife.

The encouraging part of this story is that the decline appears to be addressable rather than fixed. That is the thread that ties the laboratory work to the human trials.

What the Animal Studies Revealed

The clearest mechanistic picture comes from preclinical work, and one study in particular reframed how researchers think about vascular aging. Investigators at the University of Colorado Boulder gave aged mice nicotinamide mononucleotide, a direct NAD+ precursor, and measured what happened to their blood vessels.

The results were striking. Old mice that received NMN showed reversal of age-related decline in endothelium-dependent dilation, the ability of arteries to relax and widen properly. The improvement was tied to restored nitric oxide availability and a reduction in oxidative stress, and the effect ran through the sirtuin pathway.[2] In plain terms, boosting NAD+ made old arteries behave more like young ones.

It is worth being careful here. Mice are not people, and a result in a rodent is a hypothesis for humans, not a promise. But this study did something valuable: it identified a plausible biological mechanism, and it pointed human researchers toward the outcomes worth measuring, namely blood pressure and arterial stiffness.

Translating It to Humans: The Blood Pressure Question

That translation arrived in the form of a carefully designed human trial. Researchers ran a randomized, double-blind, placebo-controlled crossover study giving healthy middle-aged and older adults the NAD+ precursor nicotinamide riboside for six weeks. The primary goal was straightforward: confirm that oral NR could safely and effectively raise NAD+ levels in people. It did, lifting NAD+ markers meaningfully without significant side effects.[1]

The intriguing signal came in the cardiovascular data. Among participants who started with elevated blood pressure, NR supplementation was associated with a trend toward lower systolic blood pressure and reduced aortic stiffness. The authors were appropriately measured about it, writing that:

"future clinical trials should further assess the potential benefits of NR for reducing blood pressure and arterial stiffness in this group."[1]

That sentence is the sound of science being honest. A trend in a subgroup is a reason to keep looking, not a headline. So the same research group did exactly that, designing a larger trial focused specifically on midlife and older adults with above-normal systolic blood pressure to test whether three months of NR could move arterial stiffness and blood pressure in a meaningful way.[3] The cardiovascular thread that started in mice was now being pulled deliberately through human physiology.

Endothelial Function, Exercise, and the Bigger Picture

Blood pressure is only one window into cardiovascular health. Two others, endothelial function and exercise capacity, round out the picture, and NAD+ research touches both.

The endothelium is where a lot of cardiovascular aging begins. When those vessel-lining cells lose their ability to produce nitric oxide and manage oxidative stress, arteries become less responsive and more prone to dysfunction. The NAD+ pathway sits right in the middle of this, which is why so much research has focused on whether raising NAD+ can support healthier endothelial behavior.

Exercise capacity is the other piece. In a randomized study of recreationally trained adults, NMN supplementation paired with training was associated with greater improvements in aerobic capacity, the kind of measure that reflects how efficiently the heart, lungs, and muscles work together.[6] The proposed explanation centered on better oxygen utilization at the cellular level, which is consistent with NAD+'s role in energy metabolism. It is a reminder that cardiovascular fitness is not just about the heart as a pump. It is about the entire system that delivers and uses oxygen.

Research has also begun extending into clinical populations. A randomized trial explored nicotinamide riboside in people with peripheral artery disease, a condition where narrowed arteries restrict blood flow to the limbs, as part of the effort to understand where NAD+ support might fit in vascular health.[4] This is early, specialized work, but it shows how seriously the cardiovascular research community is taking the NAD+ hypothesis.

How Safe Is It, Really?

For anything touching the cardiovascular system, safety is not a footnote. It is the headline. The reassuring news is that NAD+ precursors have a growing safety record in human studies. Across the trials conducted so far, supplementation at the doses studied has generally been well tolerated, with side effects that are typically mild and infrequent.[1][5] A recent review of human clinical trials examining NAD+ precursors echoed this, concluding that the safety profile in the studied populations has been favorable while emphasizing that larger and longer trials are still needed to define long-term effects.[5]

That balance matters. The honest position is not that NAD+ therapy is proven to protect your heart. It is that the early human safety data look encouraging, the mechanism is biologically plausible, and the cardiovascular signals are interesting enough to justify continued, careful study. Anyone who tells you more than that is getting ahead of the evidence.

Building Your Cardiovascular Foundation First

No molecule replaces the fundamentals, and the cardiovascular fundamentals are some of the best established in all of medicine. Before considering anything supplemental, these are the levers that move the needle most.

• Move regularly. Aerobic exercise remains one of the most powerful tools for keeping arteries flexible and blood pressure in check. Even brisk walking counts.
• Mind your blood pressure. Know your numbers, and work with your physician if they trend upward. Small, sustained reductions add up over decades.
• Eat for your arteries. Diets rich in vegetables, whole grains, healthy fats, and lean protein, with less ultra-processed food and excess sodium, consistently support cardiovascular health.
• Protect your sleep. Poor sleep elevates blood pressure and inflammation, both of which strain the cardiovascular system over time.
• Manage stress. Chronic stress keeps the body in a state that is hard on the heart and vessels. Recovery is not a luxury; it is part of the work.

These habits are not glamorous, and they will never trend on social media. But they are the foundation on which everything else, including any consideration of NAD+ support, is built. Skipping them in favor of an injection would be backwards.

Where Physician-Guided NAD+ Therapy Fits In

For some adults who already have the fundamentals in place, the next question becomes how to support NAD+ levels more directly. Because oral precursors face questions about absorption, injectable NAD+ has drawn interest as a way to raise levels more reliably, which is part of the rationale behind clinician-supervised therapy.

At RenuviaRX, NAD+ is offered within a physician-guided framework, with board-certified physicians reviewing each person's situation and therapies compounded by a licensed pharmacy. For a system as important as your cardiovascular health, that supervision is not a formality. It is the appropriate way to make a decision that should account for your blood pressure, your medications, and your overall risk picture. NAD+ support is best understood as one consideration within a broader cardiovascular strategy, not a substitute for the basics or for the guidance of the physician who knows your history.

The Bottom Line

The cardiovascular system you carry into your fifties is shaped by chemistry you cannot see, and NAD+ is part of that chemistry. Its decline with age maps onto some of the very changes, stiffer arteries and rising blood pressure, that define cardiovascular aging. The research, from reversed vascular dysfunction in aged mice to encouraging blood pressure signals in human trials, suggests this is a story worth following closely.

What it does not suggest is a shortcut. The path to a resilient heart still runs through movement, nutrition, sleep, and regular medical care. NAD+ may turn out to be a meaningful supporting player in that story for some people, and physician-guided therapy is the responsible way to explore it. Understanding the molecule is simply the first step toward caring for the system that carries you through the rest of your life.

These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.

---

References

1. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018;9:1286. doi:10.1038/s41467-018-03421-7. Link
2. de Picciotto NE, Gano LB, Johnson LC, et al. Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice. Aging Cell. 2016;15(3):522-530. doi:10.1111/acel.12461. Link
3. Martens CR, Seals DR, et al. Nicotinamide riboside supplementation for treating elevated systolic blood pressure and arterial stiffness in midlife and older adults. Frontiers in Cardiovascular Medicine. 2022;9:881703. doi:10.3389/fcvm.2022.881703. Link
4. Brewer RC, et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nature Communications. 2024;15:5063. doi:10.1038/s41467-024-49092-5. Link
5. Song Q, Zhou X, Xu K, et al. The safety and antiaging effects of nicotinamide mononucleotide in human clinical trials: an update. Advances in Nutrition. 2023;14(6):1416-1435. Link
6. Liao B, Zhao Y, Wang D, et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. Journal of the International Society of Sports Nutrition. 2021;18(1):54. doi:10.1186/s12970-021-00442-4. Link